Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cholesterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 6/20 | 0.83 |
| ▸ | GRIN2A known ✓ | Q12879 | 6/20 | 0.83 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.79 |
| ▸ | GRIN2B known ✓ | Q13224 | 5/20 | 0.78 |
| ▸ | OSBP | P22059 | 6/20 | 0.98 |
| ▸ | RORC | P51449 | 5/20 | 0.98 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.98 |
| ▸ | USP2 | O75604 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.98 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.82 |
| ▸ | CRYAB | P02511 | 1/20 | 0.79 |
| ▸ | HMGCR | P04035 | 1/20 | 0.79 |
| ▸ | ITGAV | P06756 | 1/20 | 0.79 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.79 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.79 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.76 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.74 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL28897907 | 1.00 | OSBP (0.98) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL27726289 | 1.00 | OSBP (0.98) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL5068347 | 1.00 | OSBP (0.98) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21650234 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23579652 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23761109 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL22225160 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL22095727 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21445079 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21447271 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075746-A | Microsphere composition, preparation method thereof and application thereof in preparation of contrast agent and medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-12605354-B2 | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions | NEW FRONTIER LABS, LLC (US) | 2026-04-21 | — | — | US | claimed |
| EP-4630574-A1 | TEST SYSTEM FOR MEASURING THE ENZYME ACTIVITY OF ANGIOTENSIN-CONVERTING ENZYME (ACE) | DiaSys Diagnostic Systems GmbH (DE) | 2025-10-15 | — | — | EP | claimed |
| US-20250312287-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | POLYPLUS TRANSFECTION (FR) | 2025-10-09 | — | — | US | claimed |
| EP-4578503-A2 | NON-VIRAL IMMUNO-TARGETING | University of Washington (US) | 2025-07-02 | — | — | EP | claimed |
| CN-120059582-A | Waterproof and anticorrosive double-component cyanogen-condensation composite coating and preparation method thereof | 潍坊亚龙节能保温工程有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2025049765-A1 | TARGETING LIPID NANOPARTICLES FOR NUCLEIC ACID DELIVERY | EMD MILLIPORE CORPORATION (US) | 2025-03-06 | — | — | WO | claimed |
| CN-118766844-A | S-basedNConstruction method of 2-reaction amphiphilic alginic acid derivative/organic montmorillonite synergistically stable drug-loaded Pickering emulsion | 海南师范大学 | 2024-10-15 | — | — | CN | claimed |
| WO-2024209473-A1 | METHOD AND SYSTEM FOR PREDICTING LIVER ASSOCIATED DISEASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-10-10 | — | — | WO | claimed |
| CN-112730271-B | Liquid crystal optical fiber sensor for detecting VOC gas concentration and temperature and preparation method thereof | 哈尔滨工程大学 | 2024-09-17 | — | — | CN | claimed |
| EP-0461108-A4 | PARTIALLY FUSED PEPTIDE PELLET | — | 1992-03-18 | — | — | EP | claimed |
| EP-0461108-A1 | PARTIALLY FUSED PEPTIDE PELLET. | ENDOCON INC (US) | 1991-12-18 | — | — | EP | claimed |
| US-5039660-A | Partially fused peptide pellet | ENDOCON, INC. (US) | 1991-08-13 | — | — | US | claimed |
| EP-0357644-A4 | FLASH FLOW FUSED MEDICINAL IMPLANTS | — | 1991-01-30 | — | — | EP | claimed |
| WO-1990010437-A1 | PARTIALLY FUSED PEPTIDE PELLET | ENDOCON, INC. (US) | 1990-09-20 | — | — | WO | claimed |
| EP-0357644-A1 | FLASH FLOW FUSED MEDICINAL IMPLANTS. | ENDOCON INC (US) | 1990-03-14 | — | — | EP | claimed |
| US-4892734-A | Dispensing paste for forming medicinal pellets | ENDOCON, INC. (US) | 1990-01-09 | — | — | US | claimed |
| CN-1037456-A | The mobile fast medicinal implants that merges | ENDOCON INC (US) | 1989-11-29 | — | — | CN | claimed |
| WO-1988007816-A1 | FLASH FLOW FUSED MEDICINAL IMPLANTS | ENDOCON, INC. (US) | 1988-10-20 | — | — | WO | claimed |
| US-4748024-A | Flash flow fused medicinal implants | ENDOCON, INC. (US) | 1988-05-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312287-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | NPC1L1, CETP, LNPK | GRIN1 3816/4885GRIN2A 4254/4885ITGB3 1820/4885 |
| US-12605354-B2 | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions | LIPA, CETP, APOB | GRIN1 3771/4885GRIN2A 1550/4885ITGB3 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.